Skip to main content
S&P 5007,591.70-0.58%DOW52,064.10-0.60%NASDAQ26,081.72-0.65%BTC$77,163.00-0.95%ETH$2,458.75+0.41%GOLD$4,363.20-1.00%OIL$103.90+1.39%
Smart Investors Daily
GO

NASDAQ · GOSS

Gossamer Bio, Inc.

Healthcare · Biotechnology

$0.16

Down-$0.02 (-10.83%)

Updated Sep 10, 2026, 8:46 PM

SID Score

4.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
824.25M
P/E ratio
-5.95
Dividend yield
0.00%
52-week range
$0.11 – $3.87
Volume
23.69M
Avg. volume
3.24M

Price performance

GOSS price history

1M range · 20 trading sessions · Daily adjusted prices

GOSS closed at $0.16 after 20 trading sessions, down 10.08% for the selected period.

Last close
$0.16
Period change
-10.08%
Period low
$0.14
Period high
$0.20
Daily close
View OHLC price history
GOSS OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 9, 2026$0.15$0.1723$0.1499$0.159723.69M
Sep 8, 2026$0.1715$0.1844$0.1683$0.17996.92M
Sep 4, 2026$0.1715$0.1807$0.168$0.17538.09M
Sep 3, 2026$0.173$0.176$0.1635$0.17565.73M
Sep 2, 2026$0.1656$0.1732$0.1614$0.17275.76M
Sep 1, 2026$0.1652$0.1729$0.16$0.16747.32M
Aug 31, 2026$0.171$0.1801$0.168$0.1710.15M
Aug 28, 2026$0.172$0.1733$0.164$0.17017.92M
Aug 27, 2026$0.1761$0.1779$0.163$0.170115.45M
Aug 26, 2026$0.1991$0.2019$0.17$0.173929.15M
Aug 25, 2026$0.1796$0.2137$0.1681$0.204547.56M
Aug 24, 2026$0.15$0.1872$0.1457$0.17547.11M
Aug 21, 2026$0.1695$0.1695$0.145$0.1547131.36M
Aug 20, 2026$0.1581$0.1639$0.1505$0.15756.73M
Aug 19, 2026$0.1497$0.1585$0.142$0.15666.91M
Aug 18, 2026$0.14$0.1479$0.1382$0.14316.79M
Aug 17, 2026$0.1545$0.1556$0.14$0.1424.06M
Aug 14, 2026$0.17$0.1701$0.153$0.154213.86M
Aug 13, 2026$0.1759$0.1772$0.1654$0.170312.5M
Aug 12, 2026$0.1833$0.1856$0.173$0.17765.33M

Latest GOSS news

The latest Smart Investors Daily articles mentioning GOSS.

Stock researchCompany · Overview

GOSS research

Overview

Company profile and research snapshot.

Company profile

Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$9.00
Implied upside
—
Analysts
15
GOSS recent ratings
DateFirmRatingTarget
Aug 14, 2026Piper SandlerOverweight—
Jul 28, 2026Leerink PartnersOutperform—
Jul 27, 2026HC Wainwright & Co.Buy—
Jun 25, 2026HC Wainwright & Co.Buy—
May 26, 2026HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 4, 2026

Gossamer Bio to Present at Cantor Global Healthcare Conference

SAN DIEGO, September 04, 2026--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Company will present at the Cantor Global Healthcare Conference to take place on September 9-11, 2026.

Yahoo · Aug 27, 2026

Gossamer (GOSS) Announced Up to $250M of Financing, but Only $25M is Expected Upfront. Is the Runway Secure?

Gossamer Bio, Inc. (NASDAQ:GOSS) announced a structured private placement on August 21 that could generate up to approximately $250 million in gross proceeds. However, Gossamer Bio, Inc. (NASDAQ:GOSS) divided the financing into three stages, leaving most of the headline amount dependent on regulatory milestones. At the initial closing, Gossamer Bio, Inc. (NASDAQ:GOSS) expects approximately $25 […]

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By